BioMarin withdraws hemophilia gene therapy Roctavian
BioMarin is withdrawing Roctavian from the market after divestiture efforts failed, booking about $240M in Q4 2025 charges tied to the exit.
Image: Biomarin
Sanofi named Official Supporter of Boston 2026 Host City
Sanofi is now an Official Supporter of Boston as a 2026 World Cup Host City. Tanisha M. Sullivan joins the FIFA World Cup Boston 26 Honorary Board.
Ardelyx and LPGA announce multi-year partnership
Ardelyx and the LPGA announced a multi-year partnership. The collaboration aims to reduce stigma around digestive health issues affecting many people.
Gilead launches first Yeztugo DTC campaign with hit-song remake
Gilead’s first Yeztugo DTC campaign remakes a 2000s hit to spotlight twice-yearly PrEP dosing and position the injectable option around two visits a year.
Ipsen nominates Peter Guenter to Board of Directors
Ipsen has appointed Peter Guenter to its Board of Directors effective 28 January 2026. He fills the vacancy created by Henri Beaufour’s seat.
Novo Nordisk employees elect new board representatives
Novo Nordisk employees have elected new representatives to the Board of Directors. The new term starts after the AGM on 26 March 2026.
Essity appoints Niklas Westin Sundberg as Chief Digital & Information Officer
Essity names Niklas Westin Sundberg as CDIO, succeeding Carl-Magnus Månsson. He joins the Executive Management Team on April 15, 2026.
Bavarian Nordic: Paul Chaplin to step down as CEO
Bavarian Nordic says CEO Paul Chaplin will step down for personal reasons. He will stay through 2026 or until a successor is appointed.
medac appoints Dr. Christoph Willers as Chief Scientific Officer
The medac Group appoints Dr. Christoph Willers as CSO. He will lead research, clinical development and studies, plus pipeline and portfolio management.
Novo Nordisk to invest €432m in Athlone manufacturing site
Novo Nordisk will invest €432m in its Athlone, Ireland, tabletting plant to add manufacturing capacity for current and future oral GLP-1 therapies.